DOCSLIB.ORG

Effects of Repeated Botulinum Toxin Injections on Orbicularis Oculi Muscle

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Repeated Botulinum Toxin Injections on Orbicularis Oculi Muscle Journal of Clillical Neuro-ophthalmology 12(2): 121-127, 1992. '91992 Raven Press, Ltd., New York Effects of Repeated Botulinum Toxin Injections on Orbicularis Oculi Muscle Gary E. Borodic, M. D. and Robert Ferrante, M.S. Histologic evaluation was conducted on 12 orbicularis Botulinum A toxin has been used to treat a num­ oculi specimens from 11 patients with essential blepha­ ber of movement disorders, including benign es­ rospasm and Meige's disease who had received an av­ sential blepharospasm, facial dyskinesia associated erage of 11.3 injections of botulinum A toxin over 3.5 years. Denervation was demonstrated by the spread of with Meige's disease, spasmodic torticollis, adult­ acetylcholinesterase staining on muscle fibers when onset spasmodic torticollis, occupational hand specimens were evaluated within 11 weeks of the last dystonias, and spasmodic dysphonia (1-9). Many injection. When specimens were taken after 12 weeks, of these conditions are chronic movement disor­ spread of acetylcholinesterase was confined to the neu­ ders that require repeated injections of the toxin to romuscular junctions, with little fiber size variability re­ sembling normal muscle. Fibrosis seen in three speci­ maintain a beneficial effect. The toxin effect gener­ mens could be correlated to prior surgery. Repeated in­ ally lasts 2--4 months (1-2). jections of botulinum toxin into human muscle do not The U.s. Food and Drug Administration has re­ appear to cause irreversible muscle atrophy or other de­ cently approved botulinum A toxin for use in generative changes. Denervation changes (fiber size blepharospasm after 8 years of clinical trials. Short­ variability, acetylcholinesterase spread) appear to corre­ late to the time interval since the last injection. term side effects of botulinum A toxin for many of Key Words: Blepharospasm-Meige's syndrome, Botu­ these conditions result from local toxin spread to linum A toxin-Dystonia-Acetylcholinesterase-Hemi­ contiguous muscles (7,8). Dysphagia results from facial spasm toxin spread to the peripharyngeal muscles after higher dose injections over the sternocleiodomas­ toid muscle used for the treatment of spasmodic torticollis (8). Diplopia may be a consequence of lower eyelid injections when toxin used to treat involuntary blepharospasm spreads to the inferior oblique muscle (7). Long-term or latent clinical complications of bot­ ulinum toxic injections have not been reported. However, because therapy for many of these movement disorders requires repeated injections, there is a potential for a long-term effect of toxin administration on human muscle, In this study, we report the chronic histopathologic effects in pa­ tients who have received repeated botulinum A toxin injections into the orbicularis oculi muscle for benign essential blepharospasm or Meige's disease for at least several years. MATERIALS AND METHODS From the Massachusetts Eye and Ear Infirmary (G.E.B.) and Neuropathology Unit (R.F.), Massachusetts General Hospital, Patients involved in this study required surgical Boston, Massachusetts, U.S.A. Address correspondence and reprint requests to Dr. Gary E. intervention in two clinical situations. The first Borodic, 100 Charles River Plaza, Boston, MA 02114, U.S.A. was involutional ptosis caused by disinsertion of 121 122 G. E. BORODIC AND R. FERRANTE the attachment of the levator aponeurosis to the late the histochemical findings using various tarsal plate. To correct this condition, which often stains. involves reinsertion of the levator aponeurosis to Morphometric measurements were made with the tarsal plate, a small strip of orbicularis muscle the bioquant II system. Muscle fiber size was eval­ is removed to debulk the lid. The second clinical uated by measuring cross-sectional diameters in situation was unsatisfactory or incomplete symp­ 200 fibers in each specimen. Statistical compari­ tomatic response to botulinum toxin, which re­ sons were made using an F test, and the results sulted in the selection of an orbicularis myectomy were expressed as the mean +/- standard devia­ procedure as an alternative method of therapy. tion with variance. Each patient who became a surgical candidate The age of patients and indications for surgical for the correction of involutional disinsertion pto­ therapy are shown in Table 1. The number of bot­ sis or a myectomy procedure was advised that a ulinum toxin injections and the duration of ther­ histologic analysis of resected muscle for botuli­ apy are shown in Table 2, which also presents the num toxin activity would be conducted. Comori intervals between the last injection and the surgi­ trichrome stain and hematoxylin and eosin were cal procedure. The control values were taken from used to evaluate fiber size variability, and acetyl­ specimens removed during routine ptosis proce­ cholinesterase enzyme histochemistry was done to dures from patients who never received botulinum assess evidence of denervation. The acetylcholin­ toxin injections. Control data were derived from esterase stain has been previously reported as be­ four separate muscle specimens from three differ­ ing a valuable method of assessing denervation in ent patients. Each control patient demonstrated animal (9,10) and human striated muscle after the ptosis associated with elevated lid crease, and re­ injection of botulinum toxin (11,12). tracted preaponeurotic fat pads with good levator Specimens taken from orbicularis oculi muscle function indicating the diagnosis of involutional were immediately placed in cold (4°C) formol­ ptosis. None of the control patients had blepharo­ calcium (Baker's solution) and fixed for 6-12 hours spasm. at 4°C. Muscle specimens were cryoprotected in gum sucrose solution for 3 hours or until the tissue sank in solution. The muscle was oriented in a RESULTS longitudinal plane and frozen in a cryostat chuck using OTC compound (Tissue Tek). When the tis­ Human Specimens Treated with Repeated sue sample size permitted, the muscle was subdi­ Botulinum Toxin Injections vided and cut in longitudinal and cross-section. Cut tissue sections (10 f.lm) were adhered to gel­ The histologic response appeared to be depen­ coated slides, allowed to air dry for 2 minutes, and dent on the time interval between the last injection subsequently stained for acetylcholinesterase ac­ and the surgical procedure. The degree of acetyl­ tivity, using the method of Ceneser-Jensen and cholinesterase activity on muscle fibers was most Blackstad (13). Sections were incubated in a solu­ prominent within a period of 7-15 weeks following tion containing 13 ml maleic buffer (1.96 g maleic a therapeutic injection of botulinum toxin. Nor­ acid, 0.8 g NaOH, 10.8 ml IN NaOH, 200 ml dis­ mally, the cholinesterase staining pattern is con- tilled water), 10 mg acetylthiocholine iodide, 2 ml 0.03 M cupric sulfate, 1 ml 0.1 sodium citrate, and TABLE 1. Case history summary 0.5 mM potassium ferricyanide for 1 hour at 37°C. Contiguous cryostat sections were stained either Patient Indication for with hematoxylin and eosin or with Comori tri­ number Age Prior surgery intervention chrome stain to assess tissue morphology. 1 71 None Botox failure" To correlate the acetylcholinesterase staining 1a Myectomy Botox failure 2 59 None p~ttern Ptosis with other histochemical enzyme stains, 3. 65 None Botox failure histochemistry for myofiber ATPase activity was 4. 91 Blepharoplasty Botox failure conducted according to the method of Brooke and 5. 71 Myectomy Partial botox failure 6. 76 None Ptosis Kaiser (14), and NADH activity was assessed ac­ 7. 61 Blepharoplasty Botox failure cording to the method of Scarpelli, Hess, and 8. 78 None Ptosis Pearse (15). Acetylcholinesterase, ATPase, and 9. 71 None Ptosis 10 56 Blepharoplasty Botox failure NADH staining were conducted on five albino rab­ 11 62 None Ptosis bit longissimus dorsi muscle specimens at 5 weeks " Botulinum toxin failures underwent orbicularis myec­ after 10 lU botulinum toxin was injected to corre- tomy procedures of the upper lid and brow. ! Clin NeurfHJPhthalmol, Vol. 12, No.2, 1992 STRIATED MUSCLE AFTER BOTULINUM TOXIN INJECTIONS 123 TABLE 2. Effects of repeated botulinum toxic injections Histologic Findings Number of Cholinesterase Patient Time since injections/duration Fiber size voriability fibrosis staining number last injection of therapy (median diameter in microns) (median size in microns) Control 28.43 s = 5.29, v = 28 Focal, 12.5, s = 5.4 1:H01 1 wk 7 injections, 1.25 yr 31.8 s = 8.2, v = 66 Focal, 21, s = 8 2:H02 8wk 16 injections, 3.3 yr 30 s = 14, v = 213 Diffuse, 35.2, s = 18 + 3:AK 7wk 14 injections, 3.4 yr 27.0 s = 15.5, v = 237 Diffuse, ND + 4:RG 22wk 19 injections, 5.5 yr 25.7 s = 6.8, v = 46 Focal, 20, s = 8 5:MS 52wk 11 injections, 5.0 yr 34.4 s = 7, v = 48 Focal,25 + 6:RN 52wk 4 injections, 2.7 yr 28.1 s = 8, v = 64 Focal, 22.5, s = 6 7:EP 18 wk 12 injections, 3.0 yr 32.0 s = 9, v = 81 Focal, 19.3, s = 6.7 8:TC 7wk 11 injections, 4.0 yr 28.5 s = 17.0, v = 289 Diffuse, 161.3, s =124 9:GC 16 wk 16 injections, 4.5 yr 26.0 s = 13.5, v = 172 Diffuse, 34, s = 13 10:TP 22wk 6 injections, 2.0 yr 28.1 s = 8, v = 63 ND 11 :CP 7wk 2 injections, 1.0 yr 23.5 s = 11, v = 121 Diffuse, 147, s = 70 S, standard deviation; v, variance; ND, not determined. fined to a focal area on the muscle fiber within the The degree of acetylcholinesterase spread on mus­ neuromuscular junction (see Fig. 2). Within 15 cle fibers was inversely related to the time interval weeks after botulinum toxin injection however, from injection to biopsy (Fig. 3). there appeared to be extensive spread of enzyme Muscle fiber variability was directly related to activity throughout large surface areas of muscle the time from the last injection.
Load more

Recommended publications
  • Nerve Agent - Lntellipedia Page 1 Of9 Doc ID : 6637155 (U) Nerve Agent
    This document is made available through the declassification efforts and research of John Greenewald, Jr., creator of: The Black Vault The Black Vault is the largest online Freedom of Information Act (FOIA) document clearinghouse in the world. The research efforts here are responsible for the declassification of MILLIONS of pages released by the U.S. Government & Military. Discover the Truth at: http://www.theblackvault.com Nerve Agent - lntellipedia Page 1 of9 Doc ID : 6637155 (U) Nerve Agent UNCLASSIFIED From lntellipedia Nerve Agents (also known as nerve gases, though these chemicals are liquid at room temperature) are a class of phosphorus-containing organic chemicals (organophosphates) that disrupt the mechanism by which nerves transfer messages to organs. The disruption is caused by blocking acetylcholinesterase, an enzyme that normally relaxes the activity of acetylcholine, a neurotransmitter. ...--------- --- -·---- - --- -·-- --- --- Contents • 1 Overview • 2 Biological Effects • 2.1 Mechanism of Action • 2.2 Antidotes • 3 Classes • 3.1 G-Series • 3.2 V-Series • 3.3 Novichok Agents • 3.4 Insecticides • 4 History • 4.1 The Discovery ofNerve Agents • 4.2 The Nazi Mass Production ofTabun • 4.3 Nerve Agents in Nazi Germany • 4.4 The Secret Gets Out • 4.5 Since World War II • 4.6 Ocean Disposal of Chemical Weapons • 5 Popular Culture • 6 References and External Links --------------- ----·-- - Overview As chemical weapons, they are classified as weapons of mass destruction by the United Nations according to UN Resolution 687, and their production and stockpiling was outlawed by the Chemical Weapons Convention of 1993; the Chemical Weapons Convention officially took effect on April 291997. Poisoning by a nerve agent leads to contraction of pupils, profuse salivation, convulsions, involuntary urination and defecation, and eventual death by asphyxiation as control is lost over respiratory muscles.
    [Show full text]
  • A Screening Tool for Acetylcholinesterase Inhibitors
    RESEARCH ARTICLE Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors 1 1 2 1 Devashree N. Patil , Sushama A. Patil , Srinivas SistlaID , Jyoti P. JadhavID * 1 Department of Biotechnology, Shivaji University, Kolhapur, MS, India, 2 Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia, United States * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 Among neurodegenerative diseases, Alzheimer's disease (AD) is one of the most grievous disease. The oldest cholinergic hypothesis is used to elevate the level of cognitive impairment and acetylcholinesterase (AChE) comprises the major targeted enzyme in AD. Thus, acetylcholinesterase inhibitors (AChEI) constitutes the essential remedy for the treat- OPEN ACCESS ment of AD. The study aims to evaluate the interactions between natural molecules and Citation: Patil DN, Patil SA, Sistla S, Jadhav JP AChE by Surface Plasmon Resonance (SPR). The molecules like alkaloids, polyphenols (2019) Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors. and substrates of AChE have been considered for the study with a major emphasis on affin- PLoS ONE 14(5): e0215291. https://doi.org/ ity and kinetics. To better understand the activity of small molecules, the investigation is sup- 10.1371/journal.pone.0215291 ported by both experimental and theoretical approach such as fluorescence, Circular Editor: David A. Lightfoot, College of Agricultural Dichroism (CD) and molecular docking studies. Amongst the screened ones tannic acid Sciences, UNITED STATES showed promising results compared with others. The methodology followed here have Received: September 26, 2018 highlighted many molecules with a higher affinity towards AChE and these findings may Accepted: March 30, 2019 take lead molecules generated in preclinical studies to treat neurodegenerative diseases.
    [Show full text]
  • Acetylcholinesterase — New Roles for Gate a Relatively Long Distance to Reach the Active Site, Ache Is One of the Fastest an Old Actor Enzymes14
    PERSPECTIVES be answered regarding AChE catalysis; for OPINION example, the mechanism behind the extremely fast turnover rate of the enzyme. Despite the fact that the substrate has to navi- Acetylcholinesterase — new roles for gate a relatively long distance to reach the active site, AChE is one of the fastest an old actor enzymes14. One theory to explain this phe- nomenon has to do with the unusually strong electric field of AChE. It has been argued that Hermona Soreq and Shlomo Seidman this field assists catalysis by attracting the cationic substrate and expelling the anionic The discovery of the first neurotransmitter — understanding of AChE functions beyond the acetate product15. Site-directed mutagenesis, acetylcholine — was soon followed by the classical view and suggest the molecular basis however, has indicated that reducing the elec- discovery of its hydrolysing enzyme, for its functional heterogeneity. tric field has no effect on catalysis16.However, acetylcholinesterase. The role of the same approach has indicated an effect on acetylcholinesterase in terminating From early to recent discoveries the rate of association of fasciculin, a peptide acetylcholine-mediated neurotransmission The unique biochemical properties and phys- that can inhibit AChE17. made it the focus of intense research for iological significance of AChE make it an much of the past century. But the complexity interesting target for detailed structure–func- of acetylcholinesterase gene regulation and tion analysis. AChE-coding sequences have recent evidence for some of the long- been cloned so far from a range of evolution- a Peripheral Choline binding site suspected ‘non-classical’ actions of this arily diverse vertebrate and invertebrate binding enzyme have more recently driven a species that include insects, nematodes, fish, site profound revolution in acetylcholinesterase reptiles, birds and several mammals, among Active site research.
    [Show full text]
  • Skeletal Muscles in Chick Embryo (Cholinergic Receptor/Choline Acetyltransferase/Acetylcholinesterase/ Embryonic Development of Neuromuscular Junction) G
    Proc. Nat. Acad. Sci. USA Vol. 70, No. 6, pp. 1708-1712, June 1973 Effects of a Snake a-Neurotoxin on the Development of Innervated Skeletal Muscles in Chick Embryo (cholinergic receptor/choline acetyltransferase/acetylcholinesterase/ embryonic development of neuromuscular junction) G. GIACOBINI, G. FILOGAMO, M. WEBER, P. BOQUET, AND J. P. CHANGEUX Department of Human Anatomy, University of Turin, Turin, Italy; and Department of Molecular Biology, Institut Pasteur, Paris, France Communicated by Frankois Jacob, March 15, 1973 ABSTRACT The evolution of the cholinergic (nicotinic) The embryos were treated with a-toxin by three successive receptor in chick muscles is monitored during embryonic injections (the 3rd, 8th, and 12th day of incubation) in the yolk development with a tritiated a-neurotoxin from Naja nigri- collis and compared with the appearance of acetylcholines- sac with a Hamilton syringe, through a small window in the terase. The specific activity of these two proteins reaches a shell. Each time, 20-100 Al of a 1 mg/ml solution in sterile maximum around the 12th day of incubation. By contrast, Ringer's solution was injected. Embryos were examined the choline acetyltransferase reaches an early maximum of 16th day of incubation. About 30% of the injected embryos specific activity around the 7th day of development, and later continuously increases until hatching. Injection of died during development. a-toxin in the yolk sac at early stages ofdevelopment causes Homogenization. The tissue was added to ice-cold Ringer's an atrophy of skeletal and extrinsic ocular-muscles solution (for [3H ]a-toxin binding), to 0.5%O Triton X-100 in and of their innervation.
    [Show full text]
  • 388Fc33bdf5b91affd8650f371de
    molecules Article In Vitro and In Silico Acetylcholinesterase Inhibitory Activity of Thalictricavine and Canadine and Their Predicted Penetration across the Blood-Brain Barrier Jakub Chlebek 1,* , Jan Korábeˇcný 2,3 , Rafael Doležal 2,4,Šárka Štˇepánková 5, Daniel I. Pérez 6, Anna Hošt’álková 1 , Lubomír Opletal 1, Lucie Cahlíková 1, KateˇrinaMacáková 1, Tomáš Kuˇcera 3 , Martina Hrabinová 2,3 and Daniel Jun 2,3 1 ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; [email protected] (A.H.); [email protected] (L.O.); [email protected] (L.C.); [email protected] (K.M.) 2 Biomedical Research Center, University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Czech Republic; [email protected] (J.K.); [email protected] (R.D.); [email protected] (M.H.); [email protected] (D.J.) 3 Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Tˇrebešská 1575, 500 01 Hradec Králové, Czech Republic; [email protected] 4 Center for Basic and Applied Research, Faculty of Informatics and Management, University of Hradec Králové, Rokitanského 62, 50003 Hradec Králové, Czech Republic 5 Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentská 95, 532 10 Pardubice, Czech Republic; [email protected] 6 Centro de Investigaciones Biológicas, Avenida Ramiro de Maetzu 9, 280 40 Madrid, Spain; [email protected] * Correspondence: [email protected]; Tel.: +420-495067232; Fax: +420-495067162 Academic Editor: Derek J.
    [Show full text]
  • Acetylcholinesterase-Transgenic Mice Display Embryonic Modulations In
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 8173–8178, July 1997 Neurobiology Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin Ib gene expression followed by late-onset neuromotor deterioration (neuromuscular junctionymotoneurons) CHRISTIAN ANDRES*†‡,RACHEL BEERI*‡,ALON FRIEDMAN*, EFRAT LEV-LEHMAN*, SIVAN HENIS*, RINA TIMBERG*, MOSHE SHANI§, AND HERMONA SOREQ*¶ *Department of Biological Chemistry, The Hebrew University of Jerusalem, 91904 Israel; and §Department of Molecular Genetics, Agricultural Research Organization, The Volcani Center, Bet Dagan, 50250 Israel Communicated by Roger D. Kornberg, Stanford University School of Medicine, Stanford, CA, May 9, 1997 (received for review March 12, 1997) ABSTRACT To explore the possibility that overproduc- like domain of neurotactin was replaced with the homologous tion of neuronal acetylcholinesterase (AChE) confers changes domain from Torpedo AChE was reported to retain ligand- in both cholinergic and morphogenic intercellular interac- dependent cell-adhesive properties similar to the native mol- tions, we studied developmental responses to neuronal AChE ecule (10). This reinforced the notion that AChE may play a overexpression in motoneurons and neuromuscular junctions role in neuronal cell adhesion. of AChE-transgenic mice. Perikarya of spinal cord motoneu- In mammals, the AChE-homologous neuroligins were iden- rons were consistently enlarged from embryonic through tified as heterophilic ligands for a splice-site specific form of adult stages in AChE-transgenic mice. Atypical motoneuron the synapse-enriched neuronal cell surface protein neurexin Ib development was accompanied by premature enhancement in (11). Neurexins represent a family of three homologous genes the embryonic spinal cord expression of choline acetyltrans- (I, II, and III), giving rise to a and b forms that can undergo ferase mRNA, encoding the acetylcholine-synthesizing enzyme further alternative splicing to generate over 1,000 isoforms choline acetyltransferase.
    [Show full text]
  • Human Erythrocyte Acetylcholinesterase
    Pediat. Res. 7: 204-214 (1973) A Review: Human Erythrocyte Acetylcholinesterase FRITZ HERZ[I241 AND EUGENE KAPLAN Departments of Pediatrics, Sinai Hospital, and the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Introduction that this enzyme was an esterase, hence the term "choline esterase" was coined [100]. Further studies In recent years the erythrocyte membrane has received established that more than one type of cholinesterase considerable attention by many investigators. Numer- occurs in the animal body, differing in substrate ous reviews on the composition [21, 111], immunologic specificity and in other properties. Alles and Hawes [85, 116] and rheologic [65] properties, permeability [1] compared the cholinesterase of human erythro- [73], active transport [99], and molecular organiza- cytes with that of human serum and found that, tion [109, 113, 117], attest to this interest. Although although both enzymes hydrolyzed acetyl-a-methyl- many studies relating to membrane enzymes have ap- choline, only the erythrocyte cholinesterase could peared, systematic reviews of this area are limited. hydrolyze acetyl-yg-methylcholine and the two dia- More than a dozen enzymes have been recognized in stereomeric acetyl-«: /3-dimethylcholines. These dif- the membrane of the human erythrocyte, although ferences have been used to delineate the two main changes in activity associated with pathologic condi- types of cholinesterase: (1) acetylcholinesterase, or true, tions are found regularly only with acetylcholinesterase specific, E-type cholinesterase (acetylcholine acetyl- (EC. 3.1.1.7). Although the physiologic functions of hydrolase, EC. 3.1.1.7) and (2) cholinesterase or erythrocyte acetylcholinesterase remain obscure, the pseudo, nonspecific, s-type cholinesterase (acylcholine location of this enzyme at or near the cell surface gives acylhydrolase, EC.
    [Show full text]
  • Acetylcholinesterase: the “Hub” for Neurodegenerative Diseases And
    Review biomolecules Acetylcholinesterase: The “Hub” for NeurodegenerativeReview Diseases and Chemical Weapons Acetylcholinesterase: The “Hub” for Convention Neurodegenerative Diseases and Chemical WeaponsSamir F. de A. Cavalcante Convention 1,2,3,*, Alessandro B. C. Simas 2,*, Marcos C. Barcellos 1, Victor G. M. de Oliveira 1, Roberto B. Sousa 1, Paulo A. de M. Cabral 1 and Kamil Kuča 3,*and Tanos C. C. França 3,4,* Samir F. de A. Cavalcante 1,2,3,* , Alessandro B. C. Simas 2,*, Marcos C. Barcellos 1, Victor1 Institute G. M. ofde Chemical, Oliveira Biological,1, Roberto Radiological B. Sousa and1, Paulo Nuclear A. Defense de M. Cabral (IDQBRN),1, Kamil Brazilian Kuˇca Army3,* and TanosTechnological C. C. França Center3,4,* (CTEx), Avenida das Américas 28705, Rio de Janeiro 23020-470, Brazil; [email protected] (M.C.B.); [email protected] (V.G.M.d.O.); [email protected] 1 Institute of Chemical, Biological, Radiological and Nuclear Defense (IDQBRN), Brazilian Army (R.B.S.); [email protected] (P.A.d.M.C.) Technological Center (CTEx), Avenida das Américas 28705, Rio de Janeiro 23020-470, Brazil; 2 [email protected] Mors Institute of Research (M.C.B.); on Natural [email protected] Products (IPPN), Federal (V.G.M.d.O.); University of Rio de Janeiro (UFRJ), CCS,[email protected] Bloco H, Rio de Janeiro (R.B.S.); 21941-902, [email protected] Brazil (P.A.d.M.C.) 32 DepartmentWalter Mors of Institute Chemistry, of Research Faculty of on Science, Natural Un Productsiversity (IPPN),
    [Show full text]
  • Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives As Potent Cholinesterase Inhibitors
    biomolecules Article Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors 1,2, 1,2,3, 1,2 1,2 Barbora Svobodova y, Eva Mezeiova y, Vendula Hepnarova , Martina Hrabinova , Lubica Muckova 1,2 , Tereza Kobrlova 1 , Daniel Jun 1,2 , Ondrej Soukup 1,2, María Luisa Jimeno 4, José Marco-Contelles 3,* and Jan Korabecny 1,2,* 1 Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic 2 Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic 3 Laboratory of Medicinal Chemistry, Institute of General Organic Chemistry, Juan de la Cierva 3, 28006-Madrid, Spain 4 Centro de Química Orgánica “Lora-Tamayo” (CSIC), C/Juan de la Cierva 3, 28006-Madrid, Spain * Correspondence: [email protected] (J.M.-C.); [email protected] (J.K.); Tel.: +34-91-2587554 (J.M.-C.); +420-495-833-447 (J.K.) These authors contributed equally to this paper. y Received: 2 August 2019; Accepted: 17 August 2019; Published: 19 August 2019 Abstract: Tacrine was the first drug to be approved for Alzheimer’s disease (AD) treatment, acting as a cholinesterase inhibitor. The neuropathological hallmarks of AD are amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. The portfolio of currently approved drugs for AD includes acetylcholinesterase inhibitors (AChEIs) and N-methyl-d-aspartate (NMDA) receptor antagonist. Squaric acid is a versatile structural scaffold capable to be easily transformed into amide-bearing compounds that feature both hydrogen bond donor and acceptor groups with the possibility to create multiple interactions with complementary sites.
    [Show full text]
  • Biological Monitoring Ofexposure to Nerve Agents
    Br J Ind Med: first published as 10.1136/oem.49.9.648 on 1 September 1992. Downloaded from 648 British Journal of Industrial Medicine 1992;49:648-653 Biological monitoring of exposure to nerve agents J Bajgar Abstract occurred; at less than 30-55%, disturbed ven- Changes in acetylcholinesterase activity in tilation and fasciculations were seen, and at blood and some organs of rats after intoxica- 15-30%, convulsions occurred. Less than 10% tion with sarin, soman, VX, and 2-dimethy- was fatal. In experiments with narcotised dogs, laminoethyl-(dimethylamido)-phosphono- the blood acetylcholinesterase activity and the fluoridate (GV), in doses of roughly 2 x LD5. ability to reactivate it with trimedoxime were given intramuscularly, were obtained from determined after intoxication by intra- published data and by experiment. The time muscular administration of the four com- course of inhibition of acetylcholinesterase in pounds. It is concluded that acetylcholines- blood, regions ofbrain, and diaphragm and the terase activity in the blood corresponds to that occurrence of signs and symptoms of poison- in the target organs and can be considered as ing (none, salivation, disturbed ventilation and an appropriate parameter for biological fasciculations, convulsions, or death) were monitoring of exposure to nerve gases. More- summarised and compared. When blood over, determination of reactivation of blood enzyme activities were 70-100% normal, no acetylcholinesterase gives more information obvious signs were seen; at 60-70%, salivation than simple determination ofenzyme activity. Military Medical Academy, 502 60 Hradec Krilov6, Nerve agents are compounds ofhigh toxicity,' one of copyright. Czechoslovakia the many reasons for their possible use as chemical J Bajgar weapons.' Others from this class of chemicals Membrane Stressogenic r%tiRec spholipids.
    [Show full text]
  • Drug Treatments for Alzheimer's Disease
    Factsheet 407LP Drug treatments December 2014 for Alzheimer’s disease There are no drug treatments that can cure Alzheimer’s disease or any other common type of dementia. However, medicines have been developed for Alzheimer’s disease that can temporarily alleviate symptoms, or slow down their progression, in some people. This factsheet explains how the main drug treatments for Alzheimer’s disease work, how to access them, and when they can be prescribed and used effectively. For more information about Alzheimer’s disease see factsheet 401, What is Alzheimer’s disease? Contents n What are the main drugs used? n How do they work? n Are these drugs effective for everyone with Alzheimer’s disease? n Are there any side effects? n How are these drugs prescribed? n Are these drugs effective for other types of dementia? n Taking the drugs n Questions to ask the doctor when starting the drugs n Stopping treatment n NICE guidance: a summary n Research into new treatments n Other useful organisations. 2 Drug treatments for Alzheimer’s disease Drug treatments for Alzheimer’s disease Drug treatment for Alzheimer’s disease is important, but the benefits are small, and drugs should only be one part of a person’s overall care. Non- drug treatments, activities and support are just as important in helping someone to live well with Alzheimer’s disease. Many drugs have at least two names. The generic name identifies the substance. The brand name varies depending on the company that manufactures it. For example, a familiar painkiller has the generic name paracetamol and is manufactured under brand names such as Panadol and Calpol, among others.
    [Show full text]
  • What Killed Kim Jong-Nam? Was It the Agent Vx?
    Mil. Med. Sci. Lett. (Voj. Zdrav. Listy) 2017, vol. 86(2), p. 86-89 ISSN 0372-7025 DOI: 10.31482/mmsl.2017.013 LETTER TO THE EDITOR WHAT KILLED KIM JONG-NAM? WAS IT THE AGENT VX? INTRODUCTION Kim Jong-nam (10 May 1971 – 13 February 2017) was the eldest son of Kim Jong-il, leader of North Korea, and the estranged half-brother of North Korean dictator Kim Jong-un. From roughly 1994 to 2001, he was consid - ered the heir to his father [1]. Following a series of actions showing dissent to the North Korean regime, including a failed attempt to visit Tokyo Disneyland in May 2001 by entering Japan with a false passport, he was thought to have fallen out of favour with his father. On 13 February 2017, Kim was allegedly murdered by two women who fled after the crime [2]. The murder was commited in Malaysia during his return trip to Macau, at the low-cost carrier terminal of the Kuala Lumpur International Airport [3]. Initial reports suggest that Kim Jong-nam was mur - dered by VX, a type of agent used in chemical warfare [4]. Toxicological tests showed the presence of VX in Kim's eyes and face [5]. What is the agent VX and could this toxic substance cause the death of Kim? What is it VX? The VX is very toxic organophosphate (CAS Number 50782-69-9, O-ethyl-S-2-diisopropylaminoethyl methylphosphonothiolate) and extremely active cholinesterase inhibitor. At room temperature it is odorless, colorless to straw-colored liquid with m.p.
    [Show full text]